HealthQuill weight loss
Obesity is a health risk that needs to be tackled worldwide
Health Medical

Weight loss offers health benefits, even if pounds creep back: Study

Bharti Jayshankar March 24, 2025: University of Gothenburg researchers have uncovered a silver lining for those who struggle to maintain weight loss. According.

Read More
GLP-1 based weight-loss drugs have some therapeutic benefits, but the risks are as high
Drugs Pharma Research

New insights on GLP-1 drugs: Benefits and risks unveiled

HQ Team January 21, 2024: The popular diabetes drugs, glucagon-like peptide-1 (GLP-1) receptor agonists such as Ozempic, have gained immense popularity for their.

Read More
Danish pharmaceutical company Novo Nordisk’s combination drug achieved a 22.7% weight-loss reduction compared to a dummy drug during end-stage trials, according to a statement.
Uncategorized

Novo Nordisk says its drug CargiSema cuts body weight by 22.7% in adults

Danish pharmaceutical company Novo Nordisk’s combination drug achieved a 22.7% weight-loss reduction compared to a dummy drug during end-stage trials, according to a.

Read More
obesity
Health

Lilly’s trial results for treating obesity and pre-diabetes are promising

HQ Team November 15, 2024: Eli Lilly’s Phase III trial has yielded positive results from the SURMOUNT-1 study of tirzepatide (Zepbound and Mounjaro) for.

Read More
Eli Lilly and Company will invest one billion dollars to expand its facility in Ireland to increase its production of drugs to treat Alzheimer’s disease, diabetes and obesity, according to a company statement.
Drugs Health Pharma

Eli Lilly to invest $1b in Irish facility to make Alzheimer’s, obesity drugs

Eli Lilly and Company will invest one billion dollars to expand its facility in Ireland to increase its production of drugs to treat.

Read More
Eli Lilly and Company’s Zepbound or trizepatide injection to treat obesity reduces the risk of heart failure, hospitalisation and cardiovascular death by 38%, according to a statement from the Indianapolis-headquartered firm.
Drugs Health Pharma

Eli Lilly’s trial weight-loss drug reduces heart failure risk by 38%

Eli Lilly and Company’s Zepbound or trizepatide injection to treat obesity reduces the risk of heart failure, hospitalisation and cardiovascular death by 38%,.

Read More
The European Medicines Agency has backed Novo Nordisk’s Wegovy to expand the weight-loss drug’s application to lower heart risks and strokes in non-diabetic adults with obesity, according to a statement from the EU regulator.
Drugs Health Pharma

Wegovy gets EU regulator backing on lowering heart risks in obese people

The European Medicines Agency has backed Novo Nordisk’s Wegovy to expand the weight-loss drug’s application to lower heart risks and strokes in non-diabetic.

Read More
The UK’s Medicines and Healthcare products Regulatory Agency has approved Novo Nordisk’s weight-loss drug to cut the risk of obesity and adults suffering from heart problems or stroke.
Drugs Health Pharma

Novo Nordisk’s Wegovy gets UK regulator nod to treat heart risks

The UK’s Medicines and Healthcare products Regulatory Agency has approved Novo Nordisk’s weight-loss drug to cut the risk of obesity and adults suffering.

Read More
US-based biotechnology company Viking Therapeutics Inc., reported “positive” results from its early-stage weight-loss oral drug and the pill showed mild to moderate side effects.
Drugs Health Pharma

Viking Therapeutics’ weight-loss drug shows ‘positive’ results in early trials

US-based biotechnology company Viking Therapeutics Inc., reported “positive” results from its early-stage weight-loss oral drug and the pill showed mild to moderate side.

Read More
Obesity is a health risk that needs to be tackled worldwide
Drugs Health Pharma

Novo Nordisk unveils new drug to fight obesity, says 13% effective

HQ Team March 11, 2024: Danish drugmaker Novo Nordisk’s oral medicine, amycretin, for obesity can cause up to 13% weight loss, the company.

Read More